August 2012
-
Ascend Therapeutics is now promoting Egalet’s Sprix ketorolac tromethamine nasal spray for the treatment of moderate-to-moderately severe pain to women’s healthcare providers in the US, Egalet said. According to Egalet, the companies signed the agreement… Read more . . .
-
According to SmartInhaler maker Adherium, the FDA has granted 510(K) clearance for the company’s SmartTouch sensor for use with AstraZeneca’s Symbicort MDI. The SmartTouch device, which fits over the inhaler, records and transmits inhaler usage… Read more . . .
-
Device developer Coalesce Product Development has announced the appointments of Stephen Eason as Strategic Advisor and IP Consultant, and Mike Newton as Engineering Consultant. Both men have extensive experience in the development of OINDP devices.… Read more . . .
-
Dance Biopharm announced that it has bought back the Asia license for its Dance-501 soft mist inhaled insulin by purchasing the license holder, Harmony Biopharm Limited, from Harmony Plus Holdings Limited (Harmony). Dance said that… Read more . . .
-
RDD Online has announced that nominations are open for the 2018 Charles G. Thiel Award, and the committee will accept nominations through November 30, 2017. The award will be presented at RDD 2018, which will… Read more . . .
-
Acorda Therapeutics has received a refusal to file letter from the FDA in response to its NDA for Inbrija (CVT-301) inhaled levodopa for the treatment of OFF periods in Parkinson’s disease patients, the company said.… Read more . . .
-
Chinese inhaled drug developer and CDMO CF PharmTech has raised $65M in a Series D financing round led by Future Industry Investment Fund (managed by SDIC Fund Management), the company said. The money is to… Read more . . .
-
Propeller Health and GSK have announced that their December 2015 agreement for development of a sensor for use with the Ellipta dry powder inhaler has been expanded, and R&D activities related to the use of… Read more . . .
-
A US company is selling a device marketed under the name Loli-O that promises delivery of nebulized medication to a child in the form of a cloud that emerges around a lollipop while the child… Read more . . .
-
Altimmune has submitted an investigational new drug application to FDA for its NasoVAX intranasal flu vaccine and is planning a Phase 2 study of the product, the company said. The safety and immunogenicity study is… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland